Nexvet Biopharma Plc (NVET) Stock Price, Quote, News and Overview
NASDAQ:NVET - Nasdaq -
NVET Quote, Performance and Key Statistics
NASDAQ:NVET (7/28/2017, 11:58:59 PM)
6.72
0 (0%)
The current stock price of NVET is 6.72 null. In the past month the price increased by 0.75%. In the past year, price increased by 27.03%.
About NVET
Company Profile
NexvetBiopharma plc is a biopharmaceutical company. The company is focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies. Its product candidate consists of NV-01, is a mAb for the control of pain associated with osteoarthritis in dogs, NV-02, is a mAb for the control of pain associated with degenerative joint disease in cats and NV-08, is a receptor fusion protein for the treatment of chronic inflammatory diseases. NexvetBiopharma plc is headquartered in Blackrock, Ireland.
Company Info
Nexvet Biopharma Plc
UNIT 5 SRAGH TECHNOLOGY PARK RAHAN ROAD
TULLAMORE L2 R35 FR98
CEO: Mark Heffernan
Phone: 353-57-932-4522
Nexvet Biopharma Plc / NVET FAQ
What is the stock price of Nexvet Biopharma Plc today?
The current stock price of NVET is 6.72 null.
What is the ticker symbol for Nexvet Biopharma Plc stock?
The exchange symbol of Nexvet Biopharma Plc is NVET and it is listed on the Nasdaq exchange.
On which exchange is NVET stock listed?
NVET stock is listed on the Nasdaq exchange.
What is Nexvet Biopharma Plc worth?
Nexvet Biopharma Plc (NVET) has a market capitalization of 80.10M null. This makes NVET a Micro Cap stock.
What are the support and resistance levels for Nexvet Biopharma Plc (NVET) stock?
Nexvet Biopharma Plc (NVET) has a support level at 6.71 and a resistance level at 6.73. Check the full technical report for a detailed analysis of NVET support and resistance levels.
Should I buy Nexvet Biopharma Plc (NVET) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVET, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVET, evaluating the profitability, health, valuation and growth aspects
- Nexvet Biopharma Plc (NVET) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Nexvet Biopharma Plc (NVET) Sales and EPS estimates to see what analysts future expectations are.
- Nexvet Biopharma Plc (NVET) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Nexvet Biopharma Plc (NVET) Insider and Institutional Ownership to learn about the owners and their transactions.
- Nexvet Biopharma Plc (NVET) Stock Chart to make your own analysis
- Nexvet Biopharma Plc (NVET) Latest news and press-releases to stay up to date.
Does Nexvet Biopharma Plc (NVET) stock pay dividends?
NVET does not pay a dividend.
What is the Price/Earnings (PE) ratio of Nexvet Biopharma Plc (NVET)?
Nexvet Biopharma Plc (NVET) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).
NVET Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NVET. When comparing the yearly performance of all stocks, NVET is one of the better performing stocks in the market, outperforming 76.91% of all stocks.
NVET Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NVET. NVET has a great financial health rating, but its profitability evaluates not so good.
NVET Financial Highlights
Over the last trailing twelve months NVET reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS decreased by -4.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 100.17% | ||
| ROA | -63.8% | ||
| ROE | -72.73% | ||
| Debt/Equity | 0 |